A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 249 participants.
Also called NCT06438172
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 249 participants
- Registry
-
NCT06438172
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT06438172. Randomized; double masking; primary purpose treatment. Start 2024-03-25 (actual); primary completion 2024-12-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension
- Acronym
- HM_APOLLO
- Condition
- Hypertension
- Intervention (Drug)
- HCP1803-3
- Intervention (Drug)
- RLD2001-1
- Intervention (Drug)
- HPP2003-3
- Intervention (Drug)
- HPP2002-1
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
Record details
- Record id
cardio:ct-nct06438172- Content hash
29bfa48cf7c28e64f70ee432c2e20b79b73196427d3405787f6d92c5486df111